#heartsheet

Japan stem cell oversight system too lax?

The HeartSheet product shown here is advancing in the pipeline rapidly in part due to the Japan system of conditional approval of stem cells

The Japan stem cell and regenerative medicine oversight system has been designed to move investigational therapies forward faster than the systems in other countries such as the U.S. But how well is it working so far?

It’s an important question both for that…